Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35,089 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential usage of transcriptional repressor Zeb2 enhancers distinguishes adult and embryonic hematopoiesis.
Huang X, Ferris ST, Kim S, Choudhary MNK, Belk JA, Fan C, Qi Y, Sudan R, Xia Y, Desai P, Chen J, Ly N, Shi Q, Bagadia P, Liu T, Guilliams M, Egawa T, Colonna M, Diamond MS, Murphy TL, Satpathy AT, Wang T, Murphy KM. Huang X, et al. Among authors: liu t. Immunity. 2021 Jul 13;54(7):1417-1432.e7. doi: 10.1016/j.immuni.2021.04.015. Epub 2021 May 17. Immunity. 2021. PMID: 34004142 Free PMC article.
An Nfil3-Zeb2-Id2 pathway imposes Irf8 enhancer switching during cDC1 development.
Bagadia P, Huang X, Liu TT, Durai V, Grajales-Reyes GE, Nitschké M, Modrusan Z, Granja JM, Satpathy AT, Briseño CG, Gargaro M, Iwata A, Kim S, Chang HY, Shaw AS, Murphy TL, Murphy KM. Bagadia P, et al. Among authors: liu tt. Nat Immunol. 2019 Sep;20(9):1174-1185. doi: 10.1038/s41590-019-0449-3. Epub 2019 Aug 12. Nat Immunol. 2019. PMID: 31406377 Free PMC article.
Cryptic activation of an Irf8 enhancer governs cDC1 fate specification.
Durai V, Bagadia P, Granja JM, Satpathy AT, Kulkarni DH, Davidson JT 4th, Wu R, Patel SJ, Iwata A, Liu TT, Huang X, Briseño CG, Grajales-Reyes GE, Wöhner M, Tagoh H, Kee BL, Newberry RD, Busslinger M, Chang HY, Murphy TL, Murphy KM. Durai V, et al. Among authors: liu tt. Nat Immunol. 2019 Sep;20(9):1161-1173. doi: 10.1038/s41590-019-0450-x. Epub 2019 Aug 12. Nat Immunol. 2019. PMID: 31406378 Free PMC article.
cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity.
Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JT 4th, Bagadia P, Liu T, Briseño CG, Li L, Gillanders WE, Wu GF, Yokoyama WM, Murphy TL, Schreiber RD, Murphy KM. Ferris ST, et al. Among authors: liu t. Nature. 2020 Aug;584(7822):624-629. doi: 10.1038/s41586-020-2611-3. Epub 2020 Aug 12. Nature. 2020. PMID: 32788723 Free PMC article.
Ablation of cDC2 development by triple mutations within the Zeb2 enhancer.
Liu TT, Kim S, Desai P, Kim DH, Huang X, Ferris ST, Wu R, Ou F, Egawa T, Van Dyken SJ, Diamond MS, Johnson PF, Kubo M, Murphy TL, Murphy KM. Liu TT, et al. Nature. 2022 Jul;607(7917):142-148. doi: 10.1038/s41586-022-04866-z. Epub 2022 Jun 22. Nature. 2022. PMID: 35732734 Free PMC article.
Mechanisms of CD40-dependent cDC1 licensing beyond costimulation.
Wu R, Ohara RA, Jo S, Liu TT, Ferris ST, Ou F, Kim S, Theisen DJ, Anderson DA 3rd, Wong BW, Gershon T, Schreiber RD, Murphy TL, Murphy KM. Wu R, et al. Among authors: liu tt. Nat Immunol. 2022 Nov;23(11):1536-1550. doi: 10.1038/s41590-022-01324-w. Epub 2022 Oct 21. Nat Immunol. 2022. PMID: 36271147 Free PMC article.
35,089 results
You have reached the last available page of results. Please see the User Guide for more information.